(Q38306677)

2 September 2017

1 reference

title

Nebulization as a delivery method for mAbs in respiratory diseases (English)

1 reference

2 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Patrice Diot

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Laurent Vecellio

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Nathalie Heuzé-Vourc'h

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

5 January 2015

1 reference

Expert Opinion on Drug Delivery

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

1027-1039

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

13 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Global strategy for asthma management and prevention: GINA executive summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Antibodies to watch in 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Pharmacokinetics of intravenous immunoglobulin: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

The safety and side effects of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Effect of formulation on the stability and aerosol performance of a nebulized antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Paul Ehrlich--in search of the magic bullet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Have we overestimated the benefit of human(ized) antibodies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Antibodies as therapeutic agents: vive la renaissance!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Historical development of monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Monoclonal antibody therapy for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

21 January 2018

Anticancer antibodies

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Optimizing therapeutic antibody function: progress with Fc domain engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Interindividual variability of response to rituximab: from biological origins to individualized therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Complement function in mAb-mediated cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Neonatal Fc receptor: from immunity to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Immunoglobulin transport across polarized epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Can anti-IgE therapy prevent airway remodeling in allergic asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Nanobodies®: new ammunition to battle viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Antibody structure, instability, and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Effect of excipients on the stability and aerosol performance of nebulized aviscumine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Rationale for the selection of an aerosol delivery system for gene delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Some factors associated with the ultrasonic nebulization of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Capturing the efficiency of vibrating mesh nebulizers: minimizing upper airway deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

That's cool!--Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

On the correlation of output rate and aerodynamic characteristics in vibrating-mesh-based aqueous aerosol delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump Nebulizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

The influence of fluid physicochemical properties on vibrating-mesh nebulization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Does repeated disinfection of the e-Flow rapid nebulizer affect in vitro performance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Insulin-like growth factor-I aerosol formulations for pulmonary delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Studies on aerosol delivery of plasmid DNA using a mesh nebulizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Development and characterization of phospholipid-stabilized submicron aqueous dispersions of coenzyme Q₁₀ presenting continuous vibrating-mesh nebulization performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Inhaled proteins: challenges and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Immunogenicity of therapeutic proteins: influence of aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Immunogenicity of therapeutics: a matter of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

The lung as a route for systemic delivery of therapeutic proteins and peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Formulation strategy and use of excipients in pulmonary drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Evaluation of lung tolerance of ethanol, propylene glycol, and sorbitan monooleate as solvents in medical aerosols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

Production of functional chimaeric mouse/human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.999039

10.1517/17425247.2015.999039

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25557066%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference